Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioma 2Glioblastoma 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Head and Neck Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Temozolomide 115Bevacizumab 72Radiotherapy 52Radiation 23Erlotinib Hydrochloride 13Lomustine 12pembrolizumab 11Magnetic Resonance Spectroscopy 11Vorinostat 10Nivolumab 10Surgical Procedures, Operative 9Irinotecan 9Sorafenib 8Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 7Immunoglobulin G 7Everolimus 7Drug Therapy 7Disulfides 7Radiosurgery 6Granulocyte-Macrophage Colony-Stimulating Factor 6Carmustine 6antineoplaston AS 2-1 5antineoplaston A10 5Sirolimus 5Cilengitide 5veliparib 4veledimex 4temsirolimus 4selinexor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Glioblastoma × Re-Irradiation × Clear all
NCT01743950 2026-03-25

A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab

University of Wisconsin, Madison

Phase 2 Terminated
49 enrolled 19 charts
CNS

Glioblastoma, Glioma

NCT03661723 2024-09-19

Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma

Dana-Farber Cancer Institute

Phase 2 Completed
60 enrolled 23 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡